Sevirumab
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV) . Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL[1][2].
Product Specifications
CAS Number
[138660-96-5]
Product Name Alternative
MSL-109
UNSPSC
12352203
Target
CMV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/sevirumab.html
Purity
99.9
Solubility
H2O
Smiles
[Sevirumab]
Molecular Weight
(148.49 kDa)
References & Citations
[1]Nokta M, et al. Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109) : enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. Antiviral Res. 1994 May;24 (1) :17-26.|[2]Fouts AE, et al. Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc Natl Acad Sci U S A. 2014 Jun 3;111 (22) :8209-14.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
sc-282242 1 mg
[1,1'-Biphenyl]-2'-tetrazolo-4-carboxylic acid, [1,1'-biphenyl]-2'tetrazolo-4-ylmethyl ester (Losartan Impurity)
Ask
View Details